Details for New Drug Application (NDA): 204209
✉ Email this page to a colleague
NDA 204209 describes ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, which is a drug marketed by Larken Labs Inc and is included in one NDA. Additional details are available on the ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE profile page.
The generic ingredient in ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is acetaminophen; caffeine; dihydrocodeine bitartrate. There are sixty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acetaminophen; caffeine; dihydrocodeine bitartrate profile page.
The generic ingredient in ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is acetaminophen; caffeine; dihydrocodeine bitartrate. There are sixty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acetaminophen; caffeine; dihydrocodeine bitartrate profile page.
Summary for 204209
| Tradename: | ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE |
| Applicant: | Larken Labs Inc |
| Ingredient: | acetaminophen; caffeine; dihydrocodeine bitartrate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 325MG;30MG;16MG | ||||
| Approval Date: | Sep 30, 2016 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
